Figure 1.

Effects of atorvastatin, PCSK9 inhibitor and oestrogen on PCSK9 expression, LDLR expression, fatty acid uptake and fatty acid oxidation in mitochondria of the liver of ovariectomized prediabetic rats. A, PCSK9 expression; B, LDLR expression; C, mitochondrial CPT1 level; D, mitochondrial complex I level. E, mitochondrial complex II level; F, mitochondrial complex III level; G, mitochondrial complex IV level; and H, mitochondrial complex V level. *P < 0.05 vs NDS, ^† P < 0.05 vs HFS, ^‡ P < 0.05 vs HFOV. NDS, normal diet‐fed sham‐operated rats; HFS, high‐fat diet‐fed sham‐operated rats; HFOV, high‐fat diet‐fed ovariectomized rats; HFOA, high‐fat diet‐fed ovariectomized rats treated with atorvastatin; HFOP, high‐fat diet‐fed ovariectomized rats treated with PCSK9 inhibitor; HFOE₂, high‐fat diet‐fed ovariectomized rats treated with oestrogen; PCSK9, proprotein convertase subtilisin/kexin type 9; LDLR, low‐density lipoprotein receptor; and CPT1, carnitine palmitoyltransferase I